Tissue Repair & RecoveryPreclinical / anecdotal

GHK-Cu + BPC-157 + TB-500 blend

GLOW, Three peptide repair blend

A co formulated three peptide research blend of GHK-Cu, BPC-157, and TB-500, positioned for multi pathway tissue repair and skin quality research.

Tissue repair Skin quality Recovery Angiogenesis

Peptides in blend

Repair + skin

Research focus

None

Trials of the blend

Mechanism of action

How GLOW works

Not one molecule but a three peptide blend (GHK-Cu + BPC-157 + TB-500) that stacks collagen, repair, and angiogenic signaling into a single recovery formulation.

GLOW

3-peptide blend

GHK-Cu

Collagen

BPC-157 + TB-500

Tissue repair

Recovery

Skin and soft tissue

Also studied

GHK-Cu contributes collagen and elastin synthesis and dermal matrix support.

See related compounds

BPC-157 and TB-500 contribute soft tissue repair and growth factor signaling.

See related compounds

All three components are pro angiogenic, which also concentrates the central cancer/angiogenesis caution in one product.

See related compounds

Applications

Research applications

Multi pathway repair

Combined component effects

Animal (rodent) model

Component animal data

Skin & aesthetic

Collagen / dermal matrix

Animal (rodent) model

Component data (GHK-Cu)

Soft tissue recovery

Repair + angiogenesis

Animal (rodent) model

Component data

Bars indicate how far the evidence has progressed (in vitro to animal to human), not the size of any effect.

Full profile

Evidence, safety & status

Claimed benefits & evidence

No independent clinical evidence of its own, no trials of the combination exist. Its profile is the sum (and stacking) of its parts, all of which sit in the speculative animal/anecdote only tier.

Safety & dangers

The cancer/angiogenesis contraindication compounds here: all three components are pro angiogenic/pro growth, so the blend concentrates exactly the mechanism flagged as the central theoretical danger across this database. Combining three uncharacterized injectables also multiplies sourcing/sterility risk and makes attributing any adverse reaction impossible.

Contraindications

Active or suspected malignancy; pregnancy; the union of all three components' contraindications.

Regulatory status

Inherits component status, BPC-157 and TB-500 are in the post Category 2 grey zone (PCAC review July 23, 2026); injectable GHK-Cu is on the later track. WADA: prohibited (TB-500 named S2; BPC-157 named under S0).

Administration

Subcutaneous.

Source: Fnx Performance Peptide Research Database, a synthesis of the scientific and regulatory literature, not medical advice. Anyone considering these compounds should consult a qualified physician.

For research use only

For Research Use Only. Not for human or animal consumption. Products are sold strictly for in vitro laboratory research, not for compounding or therapeutic application.